Publication | Closed Access

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

Breast OncologyOncologyPharmacologyClinical TrialsBreast CancerPharmacotherapyMulticentre TrialCancer TreatmentMedicinePhase 3